Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab

Background Although combination treatment with bevacizumab (humanized monoclonal antibody against vascular endothelial growth factor) and chemotherapy improves survival of patients with various metastatic carcinomas, an increased risk of arterial thromboembolic events has been observed in some trial...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JNCI : Journal of the National Cancer Institute 2007-08, Vol.99 (16), p.1232-1239
Hauptverfasser:	Scappaticci, Frank A., Skillings, Jamey R., Holden, Scott N., Gerber, Hans-Peter, Miller, Kathy, Kabbinavar, Fairooz, Bergsland, Emily, Ngai, James, Holmgren, Eric, Wang, Jiuzhou, Hurwitz, Herbert
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic agents Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Arterial Occlusive Diseases - epidemiology Aspirin - administration & dosage Bevacizumab Biological and medical sciences Blood clots Cancer Carcinoma - drug therapy Carcinoma - secondary Chemotherapy Clinical trials Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Drug therapy Female Hemorrhage - epidemiology Humans Incidence Male Medical sciences Pharmacology. Drug treatments Randomized Controlled Trials as Topic Risk Factors Thromboembolism - epidemiology Tumors Venous Thrombosis - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!